Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

NCT06765954 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study was redeveloped into a new protocol

Conditions

High-risk Prostate Cancer

Interventions

DRUG: N-803 (IL-15 Superagonist)
DRUG: ETBX-071 (PSA-based Oncolytic Virus)
DRUG: M-CENK (Activated NK Cells)
RADIATION: External Beam Radiation Therapy (EBRT)
RADIATION: Androgen Deprivation Therapy (ADT)
RADIATION: Post-radiation immunotherapy

Sponsor

ImmunityBio, Inc.